This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.

Part of paid clinical trials in New York, New York.

Sponsor
iRegene Therapeutics Co., Ltd.
Study ID
NCT07102342
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Human Dopaminergic Progenitor Cells — BIOLOGICAL
    Single injection of Human Dopaminergic Progenitor Cells into the biliteral putamen/striatum regions of the brain

Study Details

This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.

Key Dates

Start date
Jan 12, 2026
Status verified
Mar 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2032

Study Design

Enrollment
5 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: NouvNeu001
    Single injection of Human Dopaminergic Progenitor Cells into the bilateral putamen/striatum regions of the brain.

Primary Outcome Measure

Safety and Tolerability [ Time Frame: 24 weeks and 48 weeks post-transplant ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cornell University Weill Medical CollegeNew YorkNew York10065-

Find similar trials in New York, NY

By condition
Parkinson's disease
By specialty
NeurologyBrain disorders
By research site
Cornell University Weill Medical College· New York, NY

Related Studies